Kazia Therapeutics

Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Ltd. is a clinical stage oncology company, which engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9M) (NASDAQ:KZIA) phase-II study of paxalisib in Primary CNS Lymphoma has been initiated at Dana-Farber Cancer Institute in Boston, Massachusetts, with the first patient enrolled to the study. Lymphoma is a cancer of white blood cells that occurs in the lymphatic system and can spread almost anywhere in the body while primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central nervous system.

Kazia Therapeutics study of paxalisib in primary CNS Lymphoma at Dana-Farber enrols first patient

SYDNEY, June 3, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced today that its CEO, Dr James Garner, will be presenting virtually at the upcoming LD Micro Invitational XI. Dr Garner commented, "this is a particularly exciting time for Kazia, with our lead program, paxalisib, now well-advanced in a pivotal study, and a promising new program, EVT801, due to enter the clinic this year.

Kazia Therapeutics to Present at LD Micro Invitational XI

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated confidence in the company's bio-tech strategy with on-market share purchases. Non-executive director Steven Coffey acquired 8,000 shares in an indirect interest on June 1 and 2, increasing his holding to 426,250 shares with another 8,015 held in a direct interest.

Kazia Therapeutics directors demonstrate confidence in bio-tech strategy with on-market purchases

Charles & Colvard

Leap Therapeutics

Benjamin Graham, the pioneer of value investing, proposed to look for stocks that have a current ratio of more than 2 and more working capital than long-term debt.

A Trio of Stocks With Solid Balance Sheets for the Value Investor

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated their confidence in the company's biotech strategy with on-market purchases. Non-executive director Steven Coffey acquired 7,250 shares at $1.40 per share in an indirect interest between April 30 and May 3, increasing the number of securities held in that interest to 418,250 shares with another 8,015 held in a direct interest.

Kazia Therapeutics directors demonstrate confidence in company with on-market purchases

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it  "a vastly stronger and more substantial business", according to CEO Dr James Garner. During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million by the end of March.

Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business"

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) recently announced an agreement with Evotec SE (FRA:EVT) to in-license the global rights to EVT801, a novel inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). Off the back of the deal, HC Wainwright & Co analysts Sean Lee, Swayampakula Ramakanth, Arthur He, Sean Kang have maintained the company's BUY rating and 12-month price target of US$17.00 per ADS.

Kazia Therapeutics' EVT801 deal secures price target of A$2.60 from Corporate Connect and BUY rating from HC Wainwright

LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for €1m upfront, €308m in milestones and tiered single-digit royalties.

Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis

Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) valuation has increased to A$346 million or A$2.68 per share from A$301 million or A$2.32 per share following the company's in-licensing of EVT801, a novel small molecule inhibitor of VEGFR3, from Evotec SE (FRA:EVT) (OTCMKTS:EVTCY) A new research report from Edison Group analyst Nathaniel Calloway highlighted the expansion of the company's product pipeline to include EVT801 as a good strategic fit while paxalisib is in the clinic. He said: "Strategically, this is an important deal for Kazia, because it enables it to expand the pipeline to multiple drugs.

Kazia Therapeutics valuation lifts off the back of in-licensing of EVT901 drug: Edison Group

Kazia Therapeutics Ltd (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) has entered into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE (FRA:EVT) – a leading European drug discovery and development company. The agreement was made for EVT801 – a small molecule, first-in class oncology drug candidate, for which Kazia expects to launch a phase-I clinical trial in 2021.

Kazia Therapeutics licenses global rights to novel, first-in class, clinic-ready oncology drug candidate EVT801

The stock price of Kazia Therapeutics Ltd (NASDAQ: KZIA) increased by 3% pre-market. This is why it happened.

KZIA Stock: 3% Increase Pre-Market Explanation

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) is in a trading halt pending an announcement in regard to a potential in-licensing transaction. In its application to the ASX for the halt, Kazia stated the announcement was pending the conclusion of negotiations.

Kazia Therapeutics halted with potential in-licensing transaction announcement pending

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has secured an increased price target from A$2.25 to A$2.60 a share by Corporate Connect analyst Marc Sinatra on the back of two recent licensing deals. The company signed an licensing deal with China-based Simcere Pharmaceutical Group Limited (HKSE:2906) for paxalisib in Greater China and earlier in March with Oasmia Pharmaceutical AB (STO: OASM) (OTCMKTS:OASMY) for worldwide rights to Cantrixil.

Kazia Therapeutics licensing deals result in A+ rating and $2.60 price target from Corporate Connect

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) will share new data from its ongoing phase II study of paxalisib in glioblastoma in a poster presentation at the prestigious American Association of Cancer Research (AACR) Annual Meeting being held virtually from April 10-15 and from May 17-21, 2021. The new pharmacokinetic (PK) data shows how long paxalisib remains in the human body and strongly supports 60-milligram once-daily dosing, confirming the company's planned administration schedule for commercial launch.

Kazia Therapeutics to present pharmacokinetic data from Paxalisib Phase II study at prestigious AACR annual meeting

LONDON, UK / ACCESSWIRE / March 30, 2021 / Kazia (NASDAQ:KZIA) has announced it has signed an agreement for the Greater China rights to paxalisib with Simcere Pharmaceuticals. The deal includes an US$11m upfront (US$7m in cash, and US$4m in an equity investment), up to US$281m in milestone payments and royalties in the mid-teens.

Kazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (HKSE:2096) to develop and commercialise Kazia's investigational new drug, paxalisib, in Greater China.  Simcere will assume responsibility for the development, registration and commercialisation of paxalisib in Greater China - which includes mainland China, Hong Kong, Macau, and Taiwan.

Kazia Therapeutics enters one of world's largest pharma markets through Chinese licensing deal for paxalisib with Simcere Pharmaceutical

The stock price of Kazia Therapeutics Ltd (NASDAQ: KZIA) increased by over 20% pre-market. This is why it happened.

KZIA Stock Price Increased Over 20% Pre-Market: Why It Happened

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd to develop and commercialize Kazia's investigational new drug, paxalisib, in Greater China. Kazia retains rights to the development and commercialization of paxalisib in all other territories and will continue to drive forward the GBM AGILE pivotal study as planned, including in China.

Kazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater China

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has been granted a trading halt by the ASX pending the release of an announcement regarding a regional licensing transaction. The halt will be in place until the start of regular trading on Tuesday, March 30, or when an announcement is released to the market, whichever occurs earliest.

Kazia Therapeutics in trading halt with regional licensing transaction news pending

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) chief executive officer and MD James Garner has highlighted the company's progress over the course of the year to date in its March newsletter, stating that the focus remains on preparing a new drug application (ND) to the US FDA. While he said the oncology-focused biotechnology company had witnessed a ‘critical watershed' in its development with the transition of paxalisib into a pivotal study for registration, Kazia was continuing to collect additional data, refining manufacturing and increasing interactions with FDA.

Kazia Therapeutics CEO and MD highlights 2021 progress with focus on providing treatment for diagnosed glioblastoma

Oasmia Pharma

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian cancer. The agreement will see Sweden-based Oasmia assume exclusive worldwide rights to develop and commercialize Cantrixil for all indications, with an initial focus on ovarian cancer.

Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (STO:OASM) (OTCMKTS:OASMY) for Cantrixil (TRX-E-002-1), a clinical-stage, first-in-class drug candidate under development for the treatment of ovarian cancer. The agreement will see Sweden-based Oasmia, an innovation-focused specialty pharmaceutical company, assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.

Kazia Therapeutics grants Oasmia exclusive rights for first-in-class ovarian cancer drug candidate Cantrixil

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) made substantial progress and achieved key milestones in the half-year ending December 31, 2020, ending the period with a cash balance of A$19.4 million and net assets of A$31.7 million. Chairman Iain Ross stated in the half-year report that in line with Kazia's ongoing focus on cost efficiency, more than 90% of its expenditure in this period was invested directly in R&D programs.

Kazia Therapeutics achieves key half-year milestones and ends period with cash balance of $19.4 million

Kazia Therapeutics (KZIA) news for Friday includes a designation from the U.S. Food and Drug Administration sending KZIA stock flying high.

News for Kazia Therapeutics Stock (KZIA)